Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
The etiology of Parkinson’s disease (PD) is significantly influenced by disease-causing changes in the protein alpha-Synuclein (aSyn). It can trigger and promote intracellular stress and thereby impair the function of dopaminergic neurons. However, these damage mechanisms do not only extend to neuronal cells, but also affect most glial cell populations, such as astroglia and microglia, but also T lymphocytes, which can no longer maintain the homeostatic CNS milieu because they produce neuroinflammatory responses to aSyn pathology. Through precise neuropathological examination, molecular characterization of biomaterials, and the use of PET technology, it has been clearly demonstrated that neuroinflammation is involved in human PD. In this review, we provide an in-depth overview of the pathomechanisms that aSyn elicits in models of disease and focus on the affected glial cell and lymphocyte populations and their interaction with pathogenic aSyn species. The interplay between aSyn and glial cells is analyzed both in the basic research setting and in the context of human neuropathology. Ultimately, a strong rationale builds up to therapeutically reduce the burden of pathological aSyn in the CNS. The current antibody-based approaches to lower the amount of aSyn and thereby alleviate neuroinflammatory responses is finally discussed as novel therapeutic strategies for PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
The human brain in numbers: a linearly scaled-up primate brain
Herculano-Houzel, S. (2009) · Frontiers in Human Neuroscience · doi:10.3389/neuro.09.031.2009 · Cited by 1,778
Microglia emerge as central players in brain disease
Salter, M. W., & Stevens, B. (2017) · Nature Medicine · doi:10.1038/nm.4397 · Cited by 1,767
Wake, H., Moorhouse, A. J., Jinno, S., Kohsaka, S., & Nabekura, J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4363-08.2009 · Cited by 1,619
A polarizing question: do M1 and M2 microglia exist?
Ransohoff, R. M. (2016) · Nature Neuroscience · doi:10.1038/nn.4338 · Cited by 1,573
Microglia in physiology and disease
Wolf, S. A., Boddeke, H. W. G. M., & Kettenmann, H. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034406 · Cited by 1,426
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 2×
“Unfortunately, longitudinal interindividual or even intraindividual analyzes are missing or are only available for small patient numbers and periods of time in which no significant alterations have been observed [107].”
Backgroundα-Synuclein strains cause distinct synucleinopathies after local and systemic administration
Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., Van den Haute, C., Melki, R., & Baekelandt, V. (2015) · Nature · doi:10.1038/nature14547 · Cited by 1,130 · cited 2×
“Even after intravenous injection, aSyn crosses the blood brain barrier [28], or is found in the contralateral hemisphere of wild type mice following previous injection of aSyn into the ipsilateral striatum [29].”
BackgroundLee, H.-J., Suk, J.-E., Patrick, C., Bae, E.-J., Cho, J.-H., Rho, S., Hwang, D., Masliah, E., & Lee, S.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081125 · Cited by 877 · cited 1×
“In cell culture, aSyn was a strong TLR-4 mediated stimulation factor for astrocytes and was taken up by these via endocytosis [33], so that it can be assumed that astrocytes contribute significantly to the clearance and degradation of extracellular aSyn.”
BackgroundAccuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis
Rizzo, G., Copetti, M., Arcuti, S., Martino, D., Fontana, A., & Logroscino, G. (2016) · Neurology · doi:10.1212/wnl.0000000000002350 · Cited by 870 · cited 1×
“This may not least be due to the fact that the clinical diagnosis of PD continues to be associated with uncertainties [68].”
BackgroundT cells from patients with Parkinson’s disease recognize α-synuclein peptides
Sulzer, D., Alcalay, R. N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., Liong, C., McMurtrey, C., Hildebrand, W. H., Mao, X., et al. (2017) · Nature · doi:10.1038/nature22815 · Cited by 866 · cited 2×
“Here, the MHC class II response may precede MHC class I, and it was noted in the Sulzer manuscript that exposing microglia to aSyn activated MHC class I expression by dopamine neurons [105].”
BackgroundObeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
Kim, C., Ho, D.-H., Suk, J.-E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2534 · Cited by 856 · cited 1×
“Extracellular aSyn released from neuronal cells was demonstrated in an elegant study using in silico, in vitro, and in vivo approaches to be an endogenous agonist for Toll-like receptor 2 (TLR2), which activates inflammatory responses in microglia [51].”
BackgroundImamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791 · cited 1×
“Other brain regions, such as putamen, hippocampus, transentorhinal cortex, or cingulus gyrus, also exhibited increased microglial cell populations [86].”
BackgroundVolpicelli-Daley, L. A., Luk, K. C., & Lee, V. M.-Y. (2014) · Nature Protocols · doi:10.1038/nprot.2014.143 · Cited by 731 · cited 1×
“Interestingly, there was no need for an overexpression of wild-type aSyn because the presence of endogenous aSyn was sufficient [24,25].”
BackgroundGlial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701 · cited 3×
“In the neuropathological studies, the degeneration of dopaminergic nigral neurons and Lewy-body pathology were in focus first [72], but soon after the involvement of extra-nigral brain regions [73] and glial pathology was appreciated [74].”
BackgroundToll‐like receptor 4 is required for α‐synuclein dependent activation of microglia and astroglia
Fellner, L., Irschick, R., Schanda, K., Reindl, M., Klimaschewski, L., Poewe, W., Wenning, G. K., & Stefanova, N. (2013) · Glia · doi:10.1002/glia.22437 · Cited by 697
Graeber, M. B. (2010) · Science · doi:10.1126/science.1190929 · Cited by 608 · cited 1×
“The functional phenotype of the reactive microglia strongly depends on distinct stimulating factors at the beginning or during the progression of PD, and on the respective localization in the CNS [45,46], so that the M1/M2 concept for the differentiated function of the microglia seems to be rather simplified [47].”
BackgroundNitric oxide synthase and neuronal vulnerability in parkinson's disease
Hunot, S., Boissière, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., & Hirsch, E. C. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00578-1 · Cited by 595 · cited 1×
“An increased expression of these enzymes can be found in post mortem analyzes in the SN of PD patients [88,89].”
BackgroundInflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2
Knott, C., Stern, G., & Wilkin, G. P. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0914 · Cited by 503 · cited 1×
“An increased expression of these enzymes can be found in post mortem analyzes in the SN of PD patients [88,89].”
BackgroundBraak, H., Sastre, M., & Del Tredici, K. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0244-3 · Cited by 462 · cited 3×
“The expression of aSyn in astrocytes in PD human brains is rather low, but it has been found in various aggregation states [77,81].”
BackgroundCroisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K., & Graeber, M. B. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-14 · Cited by 414
Braak, H., & Del Tredici, K. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179001 · Cited by 372
Clearance and deposition of extracellular α-synuclein aggregates in microglia
Lee, H.-J., Suk, J.-E., Bae, E.-J., & Lee, S.-J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.05.045 · Cited by 343 · cited 1×
“Beside this inflammatory response, microglia cells are directly involved in the clearance mechanism of aSyn [56].”
BackgroundHuman Astrocytes Transfer Aggregated Alpha-Synuclein via Tunneling Nanotubes
Rostami, J., Holmqvist, S., Lindström, V., Sigvardson, J., Westermark, G. T., Ingelsson, M., Bergström, J., Roybon, L., & Erlandsson, A. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.0983-17.2017 · Cited by 339 · cited 1×
“In return, the endangered astrocytes received energy-providing mitochondria from the healthier cells [37].”
BackgroundAntibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission
Bae, E.-J., Lee, H.-J., Rockenstein, E., Ho, D.-H., Park, E.-B., Yang, N.-Y., Desplats, P., Masliah, E., & Lee, S.-J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1292-12.2012 · Cited by 339
Alterations of T-lymphocyte populations in Parkinson disease
Baba, Y., Kuroiwa, A., Uitti, R. J., Wszolek, Z. K., & Yamada, T. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.07.005 · Cited by 336
Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease
Troncoso-Escudero, P., Parra, A., Nassif, M., & Vidal, R. L. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00860 · Cited by 191
Dupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182 · cited 1×
“In contrast, the PET technology for specific labeling of microglial cells has improved and could be integrated with the use of second-generation microglial TSPO tracers [130].”
BackgroundExtracellular α-synuclein levels are regulated by neuronal activity
Yamada, K., & Iwatsubo, T. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0241-0 · Cited by 148 · cited 1×
“demonstrated recently that the release of aSyn in vivo is also regulated by neuronal activity, as well as by extrinsic mechanisms and stressors [23].”
BackgroundBiobanking of CSF: International standardization to optimize biomarker development
Teunissen, C. E., Tumani, H., Engelborghs, S., & Mollenhauer, B. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.12.024 · Cited by 137
Emerging Immunotherapies for Parkinson Disease
Zella, S. M. A., Metzdorf, J., Ciftci, E., Ostendorf, F., Muhlack, S., Gold, R., & Tönges, L. (2019) · Neurology and Therapy · doi:10.1007/s40120-018-0122-z · Cited by 64
Self-citationImmune-mediated processes in neurodegeneration: where do we stand?
Fakhoury, M. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8052-0 · Cited by 43 · cited 1×
“The proteins of the MHC complex are a central element in immune regulation and present antigenic structures that can activate T lymphocytes [61].”
Background
Cited by
The Contribution of Microglia to Neuroinflammation in Parkinson’s Disease
Badanjak, K., Fixemer, S., Smajić, S., Skupin, A., & Grünewald, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094676 · Cited by 276
The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases
Zang, X., Chen, S., Zhu, J., Ma, J., & Zhai, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.872134 · Cited by 139
Mapping microglia and astrocyte activation in vivo using diffusion MRI
Garcia-Hernandez, R., Cerdán Cerdá, A., Trouve Carpena, A., Drakesmith, M., Koller, K., Jones, D. K., Canals, S., & De Santis, S. (2022) · Science Advances · doi:10.1126/sciadv.abq2923 · Cited by 102
Huntington, T. E., & Srinivasan, R. (2021) · Aging and disease · doi:10.14336/ad.2021.0517 · Cited by 34
“One interesting finding in this regard is that the abnormal accumulation of a-syn in astrocytes results in altered glutamate clearance [176].”
Background
Metadata
- Authors
- Zella, M. A. S., Metzdorf, J., Ostendorf, F., Maass, F., Muhlack, S., Gold, R., Haghikia, A., & Tönges, L.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-01-31
- Volume
- 8
- Issue
- 2
- Pages
- 105
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W2912394781
- Cited by
- 43
- References
- 35
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.